<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641081</url>
  </required_header>
  <id_info>
    <org_study_id>LAC-MD-21</org_study_id>
    <nct_id>NCT01641081</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma</brief_title>
  <official_title>Phase II, Randomized, Placebo-controlled, Double-blind, Double-dummy, 5-period Complete Crossover Study of the Bronchodilator Effects of Formoterol Fumarate Inhalation Powder in Patients With Mild to Moderate Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol
      fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to
      moderate asthma.

      This study will include a screening visit followed by a 4 month treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)</measure>
    <time_frame>Baseline and up to 6 hrs post-dose (±15 min) on Day 14 of treatment</time_frame>
    <description>AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)</measure>
    <time_frame>Baseline and up to 6 hrs post-dose (±15 min) on Day 1 of treatment</time_frame>
    <description>AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Foradil Aerolizer, Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Foradil Aerolizer, High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate in the Pressair DPI, Low Dose</intervention_name>
    <description>Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate in the Pressair DPI, High Dose</intervention_name>
    <description>Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foradil Aerolizer, Low Dose</intervention_name>
    <description>Foradil Aerolizer 12 micrograms, twice a day for 14 days</description>
    <arm_group_label>Active Comparator 1</arm_group_label>
    <other_name>Formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foradil Aerolizer, High Dose</intervention_name>
    <description>Foradil Aerolizer 24 micrograms, twice per day for 14 days</description>
    <arm_group_label>Active Comparator 2</arm_group_label>
    <other_name>Formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in the Pressair for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusions:

          -  Patients with mild-to-moderate asthma for at least 6 months prior to Visit 1 (as
             defined in the GINA Guidelines) which is unlikely to exacerbate during the study
             (e.g., due to seasonal allergen exposure).

          -  Patients must be on a stable dose of Inhaled Corticosteroids (ICS) for at least 30
             days prior to Visit 1. Patients on a combination of ICS/LABA must discontinue the use
             of LABA and must be on a stable dose of ICS for 30 days prior to Visit 1.

          -  Qualifying spirometry at Visit 1 demonstrates highest FEV1 is ≤ 85% and ≥ 60% of
             predicted for age, height, and gender using NHANES III (NHANES 2010) when
             bronchodilator medications have been withheld the appropriate length of time per the
             List of Concomitant Medications (Appendix III)

          -  Patient demonstrates reversibility with an increase in FEV1 of 12% and 200 mL after
             the administration of 360 µg of albuterol.

          -  Highest pre-dose FEV1 at Visits 2, 4, 6, 8, and 10 must be within 25% of the
             qualifying FEV1 at Visit 1

        Exclusions:

          -  Patients with any clinically significant respiratory conditions other than mild to
             moderate asthma, such as COPD, active tuberculosis, or history of interstitial lung
             disease

          -  Patients with a severe asthma exacerbation requiring hospitalization in the previous
             12 months

          -  Patient is not able to withhold use of inhaled short-acting beta-agonist (SABA) for at
             least 6 hours prior to visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forest Investigative Site 909</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2066</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1624</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1995</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1347</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1996</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1137</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1998</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2047</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1536</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1333</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1431</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2041</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1599</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1609</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1999</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1153</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1134</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1806</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1176</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2043</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1580</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2025</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1155</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1332</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1370</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1699</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2011</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1997</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4059&amp;filename=LAC-MD-21_CSRredacted.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <results_first_submitted>October 27, 2016</results_first_submitted>
  <results_first_submitted_qc>October 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2016</results_first_posted>
  <disposition_first_submitted>February 13, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 13, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2013</disposition_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 29 study centers in the United States
First patient visit was in June 2012 and last patient visit was in February 2013</recruitment_details>
      <pre_assignment_details>A total of 408 patients were screened; there were 234 screen failures, primarily (225/234) because inclusion/exclusion criteria were not met</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>24 μg Foradil Aerolizer; 12 μg Foradil Aerolizer; Placebo Pressair; Formoterol 12 μg Pressair; Formoterol 6 μg Pressair</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>12 μg Foradil Aerolizer; Formoterol 12 μg Pressair; 24 μg Foradil Aerolizer; Formoterol 6 μg Pressair; Placebo Pressair</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Formoterol 12 μg Pressair; Formoterol 6 μg Pressair; 12 μg Foradil Aerolizer; Placebo Pressair; 24 μg Foradil Aerolizer</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Formoterol 6 μg Pressair; Placebo Pressair; Formoterol 12 μg Pressair; 24 μg Foradil Aerolizer; 12 μg Foradil Aerolizer</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5</title>
          <description>Placebo Pressair; 24 μg Foradil Aerolizer; Formoterol 6 μg Pressair; 12 μg Foradil Aerolizer; Formoterol 12 μg Pressair</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6</title>
          <description>Formoterol 6 μg Pressair; Formoterol 12 μg Pressair; Placebo Pressair; 12 μg Foradil Aerolizer; 24 μg Foradil Aerolizer</description>
        </group>
        <group group_id="P7">
          <title>Sequence 7</title>
          <description>Placebo Pressair; Formoterol 6 μg Pressair; 24 μg Foradil Aerolizer; Formoterol 12 μg Pressair; 12 μg Foradil Aerolizer</description>
        </group>
        <group group_id="P8">
          <title>Sequence 8</title>
          <description>24 μg Foradil Aerolizer; Placebo Pressair; 12 μg Foradil Aerolizer; Formoterol 6 μg Pressair; Formoterol 12 μg Pressair</description>
        </group>
        <group group_id="P9">
          <title>Sequence 9</title>
          <description>12 μg Foradil Aerolizer; 24 μg Foradil Aerolizer; Formoterol 12 μg Pressair; Placebo Pressair; Formoterol 6 μg Pressair</description>
        </group>
        <group group_id="P10">
          <title>Sequence 10</title>
          <description>Formoterol 12 μg Pressair; 12 μg Foradil Aerolizer; Formoterol 6 μg Pressair; 24 μg Foradil Aerolizer; Placebo Pressair</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="17"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor request (potential unblinding)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
          <description>All patients participating in the crossover study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)</title>
        <description>AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals</description>
        <time_frame>Baseline and up to 6 hrs post-dose (±15 min) on Day 14 of treatment</time_frame>
        <population>Intent to treat (ITT) Population defined as all patients in the Safety Population who had a baseline and at least 1 post-baseline FEV1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Foradil 24 μg</title>
            <description>Administered via Aerolizer</description>
          </group>
          <group group_id="O2">
            <title>Foradil 12 μg</title>
            <description>Administered via Aerolizer</description>
          </group>
          <group group_id="O3">
            <title>Formoterol 12 μg</title>
            <description>Administered via Pressair</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 6 μg</title>
            <description>Administered via Pressair</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Administered via Pressair</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)</title>
          <description>AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals</description>
          <population>Intent to treat (ITT) Population defined as all patients in the Safety Population who had a baseline and at least 1 post-baseline FEV1 assessment</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="159"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3196" spread="0.0382"/>
                    <measurement group_id="O2" value="0.3076" spread="0.0382"/>
                    <measurement group_id="O3" value="0.2795" spread="0.0382"/>
                    <measurement group_id="O4" value="0.2726" spread="0.0381"/>
                    <measurement group_id="O5" value="0.0552" spread="0.0382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.2644</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0148</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2353</ci_lower_limit>
            <ci_upper_limit>0.2934</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.2524</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0156</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2218</ci_lower_limit>
            <ci_upper_limit>0.2830</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.2242</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0153</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1941</ci_lower_limit>
            <ci_upper_limit>0.2544</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.2174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0146</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1887</ci_lower_limit>
            <ci_upper_limit>0.2461</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)</title>
        <description>AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals</description>
        <time_frame>Baseline and up to 6 hrs post-dose (±15 min) on Day 1 of treatment</time_frame>
        <population>Intent to treat (ITT) Population defined as all patients in the Safety Population who had a baseline and at least 1 post-baseline FEV1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Foradil 24 μg</title>
            <description>Administered via Aerolizer</description>
          </group>
          <group group_id="O2">
            <title>Foradil 12 μg</title>
            <description>Administered via Aerolizer</description>
          </group>
          <group group_id="O3">
            <title>Formoterol 12 μg</title>
            <description>Administered via Pressair</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 6 μg</title>
            <description>Administered via Pressair</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Administered via Pressair</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)</title>
          <description>AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals</description>
          <population>Intent to treat (ITT) Population defined as all patients in the Safety Population who had a baseline and at least 1 post-baseline FEV1 assessment</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3544" spread="0.0196"/>
                    <measurement group_id="O2" value="0.3068" spread="0.0198"/>
                    <measurement group_id="O3" value="0.2712" spread="0.0197"/>
                    <measurement group_id="O4" value="0.2204" spread="0.0197"/>
                    <measurement group_id="O5" value="0.0306" spread="0.0198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 14±1 of the final treatment period (Period 5)</time_frame>
      <desc>The Safety Population consisted of all patients screened, randomized to a treatment sequence, and who took at least one dose of double-blind investigational product The total number of patients in the Safety Population was 174; due to study drop-out and the crossover study design, not all patients received all treatments</desc>
      <group_list>
        <group group_id="E1">
          <title>Foradil 24 μg</title>
          <description>Administered via Aerolizer</description>
        </group>
        <group group_id="E2">
          <title>Foradil 12 μg</title>
          <description>Administered via Aerolizer</description>
        </group>
        <group group_id="E3">
          <title>Formoterol 12 μg</title>
          <description>Administered via Pressair</description>
        </group>
        <group group_id="E4">
          <title>Formoterol 6 μg</title>
          <description>Administered via Pressair</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Administered via Pressair</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of the results by the PI will be subject to mutual agreement between the PI and sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

